9JV0 Stock Overview
Engages in the development of ophthalmic drugs for medical needs in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Redwood Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.22 |
| 52 Week High | kr3.24 |
| 52 Week Low | kr0.057 |
| Beta | 0.45 |
| 11 Month Change | 209.19% |
| 3 Month Change | 104.61% |
| 1 Year Change | -93.15% |
| 33 Year Change | -99.66% |
| 5 Year Change | n/a |
| Change since IPO | -99.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9JV0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 122.0% | -7.0% | -3.5% |
| 1Y | -93.1% | -16.7% | 1.7% |
Return vs Industry: 9JV0 underperformed the German Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: 9JV0 underperformed the German Market which returned 1.7% over the past year.
Price Volatility
| 9JV0 volatility | |
|---|---|
| 9JV0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 9JV0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 9JV0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1 | MV Vidaeus | www.redwoodpharma.se |
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Redwood Pharma AB Fundamentals Summary
| 9JV0 fundamental statistics | |
|---|---|
| Market cap | €684.67k |
| Earnings (TTM) | -€1.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 9JV0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9JV0 income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr13.60m |
| Earnings | -kr13.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9JV0 perform over the long term?
See historical performance and comparison